Schering-Plough 4Q Revenues: $2.7 billion (+14%) 4Q Earnings: $204 million (+62%) FY Revenues: $10.6 billion (+11%) FY Earnings: $1.1 billion (earnings were $269 million FY2005) Comments: In the quarter, Remicade sales were up 34% to $337 million, Nasonex sales were up 37% to $253 million, Temodar sales grew 18% to $189 million and Clarinex sales were $164 million, up 18%. FY sales (excluding cholesterol joint venture sales) grew 11% versus 2005, with leading prescription...